Información Científica

Sitagliptin Added to Ongoing Metformin Therapy Enhanced Glycemic Control and Beta-Cell Function in Patients with Type 2 Diabetes. Avraham Karasik, Bernard Charbonnel, Ji Liu,  Mei Wu,  Alan Meehan,  and Gary Meininger. Chaim Sheba Medical Center, Tel Hashomer, Israel; Clinique d'Endocrinologie, Nantes Cedex, France; Merck Research Laboratories, Rahway, NJ. Ver póster

Multiple Dose Administration of Sitagliptin, A Dipeptidyl Peptidase-4 Inhibitor, in Healthy Japanese Subjects. Hirohisa Narita, Kenji Nonaka,  Cathy Stevens, Kotoba Okuyama, Go Fujimoto, Karen Snyder,Deborah Hilliard.  Banyu Pharmaceutical CO., LTD., Tokyo, Tsukuba, Japan; 2 Merck & Co.,Inc., Rahway, NJ, United States. Ver póster

Direct Comparison of Efficacy and Durability of DPP-4 Inhibitor, PPARg Agonist and Sulfonylurea on Glycemic Control and b-Cell Function in a Rodent Model of Type 2 Diabetes.
James Mu, John Woods, Yun-Ping Zhou, Zhihua Li, Emanuel Zycband, Yue Feng, Lan Zhu, Andrew Howard, Ranabir Sinha Roy, Cai Li, Nancy A. Thornberry,1 Bei B. Zhang
Metabolic Disorders-Diabetes, 2Target Validation; Merck Research Laboratories, Rahway, NJ 07065. Ver póster